Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded Healthcare sector company. As of May 20, 2026, CRVS trades at $12.33 with a market cap of $1.03B and a P/E ratio of -64.19. CRVS moved +5.83% today. Year to date, CRVS is +79.53%; over the trailing twelve months it is +231.25%. Its 52-week range spans $2.54 to $26.95. Analyst consensus is strong buy with an average price target of $31.60. Rallies surfaces CRVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Corvus Ends Q1 with $236.7M Cash, Advances Soquelitinib into Phase 2 and 3 Trials: Corvus ended Q1 with $236.7M in cash following a $189.4M January financing. The company advanced its ITK inhibitor soquelitinib with Phase 1 atopic dermatitis results, initiated a Phase 2 AD trial and plans Phase 2 hidradenitis suppurativa and asthma studies plus a registrational Phase 3 PTCL study.
| Metric | Value |
|---|---|
| Price | $12.33 |
| Market Cap | $1.03B |
| P/E Ratio | -64.19 |
| EPS | $-0.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.95 |
| 52-Week Low | $2.54 |
| Volume | 1.99M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-15.28M |
| Gross Margin | 0.00% |
5 analysts cover CRVS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.60.